Stockscreener 앱 받기
19.86
2.16%
0.42
시간 외 거래:
19.86
전일 마감가:
$19.44
열려 있는:
$19.482
하루 거래량:
942.30K
Relative Volume:
1.07
시가총액:
$1.47B
수익:
$97.36M
순이익/손실:
$-172.42M
주가수익비율:
-8.6408
EPS:
-2.2984
순현금흐름:
$-188.84M
1주 성능:
+5.58%
1개월 성능:
+31.96%
6개월 성능:
+50.80%
1년 성능:
+114.94%
1일 변동 폭
$19.46
$20.60
1주일 범위
$18.80
$21.26
52주 변동 폭
$6.92
$21.26
Xencor Inc Stock (XNCR) Company Profile
명칭
Xencor Inc
전화
626-305-5900
주소
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
19.86 | 1.44B | 97.36M | -172.42M | -188.84M | -2.2984 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-10-29 | 업그레이드 | Barclays | Underweight → Overweight |
| 2025-09-17 | 재개 | Barclays | Underweight |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-04-21 | 개시 | William Blair | Outperform |
| 2024-12-12 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | 재확인 | BTIG Research | Buy |
| 2024-02-28 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | 개시 | BofA Securities | Buy |
| 2022-12-06 | 개시 | Cowen | Outperform |
| 2022-10-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-21 | 개시 | SMBC Nikko | Outperform |
| 2021-12-15 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-02-24 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | 개시 | Barclays | Underweight |
| 2020-02-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-01-30 | 개시 | RBC Capital Mkts | Outperform |
| 2019-11-20 | 재개 | Guggenheim | Neutral |
| 2019-08-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-04-12 | 개시 | Guggenheim | Buy |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2019-03-15 | 개시 | Raymond James | Outperform |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2017-03-02 | 개시 | Instinet | Neutral |
| 2017-03-02 | 재확인 | Wedbush | Outperform |
| 2016-10-04 | 개시 | Piper Jaffray | Overweight |
| 2015-12-22 | 개시 | Canaccord Genuity | Buy |
| 2015-08-05 | 재확인 | MLV & Co | Buy |
| 2015-02-12 | 재확인 | Oppenheimer | Outperform |
| 2015-01-28 | 재확인 | MLV & Co | Buy |
| 2014-07-11 | 개시 | Oppenheimer | Outperform |
모두보기
Xencor Inc 주식(XNCR)의 최신 뉴스
Xencor Inc (XNCR) Income Statement - TradingKey
Xencor Inc (XNCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xencor Inc (XNCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Xencor Inc (XNCR) Balance Sheet - TradingKey
Xencor Inc (XNCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ETFs Investing in Xencor, Inc. Stocks - TradingView
Xencor, Inc. Revenue Breakdown – DUS:XE9 - TradingView
Xencor Inc (XNCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo! Finance Canada
Xencor (NASDAQ:XNCR) Stock Price Down 6.7%Should You Sell? - MarketBeat
(XNCR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Xencor (NASDAQ:XNCR) Hits A High: Can Momentum Last? - Kalkine Media
Xencor stock hits 52-week high at 18.83 USD - Investing.com India
Xencor (NASDAQ:XNCR) Sets New 52-Week HighShould You Buy? - MarketBeat
Xencor stock hits 52-week high at 18.83 USD By Investing.com - Investing.com South Africa
Xencor (NASDAQ:XNCR) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Xencor Shares Kidney Cancer Trial Results at ESMO - t.co
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma - BioSpace
Xencor shows strong pipeline progress with prom... - Pluang
Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data - Seeking Alpha
Xencor (XNCR) Shares Jump 17% Following ESMO 2026 Announcement - GuruFocus
Xencor (NASDAQ:XNCR) Stock Price Up 7.9%What's Next? - MarketBeat
Xencor’s XmAb819 data to be presented at ESMO congress By Investing.com - Investing.com South Africa
Xencor’s XmAb819 data to be presented at ESMO congress - Investing.com
Xencor to present Phase 1 XmAb819 data in advanced kidney cancer at ESMO 2026 - Bitget
Pharmaceutical Method-of-Use Claims After Teva v. Eli Lilly and In re Xencor: Written Description, Enablement, and the Known-Compound Genus - The National Law Review
Xencor: Bullish On Their Increasingly In-House Pipeline (NASDAQ:XNCR) - Seeking Alpha
Xencor (NASDAQ:XNCR) Shares Down 6.6%Should You Sell? - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Xencor Inc. (XNCR) Faces Pressure as Shares Slide Toward Key SupportQuality Factor - dars.gov.et
Form 4 Xencor Inc For: 8 July By Investing.com - Investing.com Nigeria
Ellen Feigal at Xencor (XNCR) receives RSUs and options equity awards - Stock Titan
Xencor (XNCR) awards RSUs and stock options to director Gorman - Stock Titan
Xencor (XNCR) director Kurt Gustafson granted RSUs and stock options - Stock Titan
[Form 4] Xencor Inc Insider Trading Activity - Stock Titan
Xencor (XNCR) director granted RSUs and stock options in equity award - Stock Titan
Xencor (XNCR) director granted RSUs and 20,604 stock options at $12.20 - Stock Titan
Xencor (NASDAQ: XNCR) awards director stock grants vesting within a year - Stock Titan
Xencor (NASDAQ: XNCR) director receives new RSU and stock option grant - Stock Titan
Frontier tech research, news & data - MLQ.ai
Truist Financial Maintains Xencor(XNCR.US) With Buy Rating, Cuts Target Price to $27 - Moomoo
XENCOR Maintains Buy Rating -- Price Target Lowered to $27.00 by Truist Securities - GuruFocus
XNCRXencor Inc Revenue Breakdown - Finviz
Xencor (XNCR) Declines 4.5% as Selling Pressure Builds Near SupportTurnaround Stocks - dars.gov.et
Enterprise value to revenue forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Price to earnings forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Enterprise value to EBIT forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Price to sales forward of Xencor, Inc. – NASDAQ:XNCR - TradingView
Price to sales forward of Xencor, Inc. – TRADEGATE:XE9 - TradingView
Xencor (XNCR) Surges Over 6% as Biotech Sector Momentum Drives Shares Toward Key ResistanceInsider Selling Alerts - dars.gov.et
Xencor Inc (XNCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):